Skip to main content
OpenTrials
Completed

NCT Number: NCT03317873

The Effect of Genetic Variation in TMPRSS6 Gene (SNP rs855791) on Oral Iron Absorption: an Iron Stable Isotope Study

Iron deficiency is considered the most common nutritional deficiency worldwide and affects children and women in both non-industrialized as well as industrialized countries. The main regulatory molecule of iron metabolism is hepcidin, a hormone produced in the liver that regulates intestinal iron absorption, placental transport, recycling of iron by macrophages and release from stores. The expression of hepcidin is regulated by many mediators, one of which is Matriptase-2 - a transmembrane protease. Complete loss of function leads to the rare disease iron-refractory iron deficiency anemia (IRIDA). Matriptase-2 is encoded by the gene TMPRSS6 and the single nucleotide polymorphism (SNP) rs855791 causes a non-synonymous substitution (V736A) that reduces the activity of the protease to inhibit hepcidin transcription. Genome wide association studies have identified the TMPRSS6 SNP rs855791 has a strong association with red blood cell and iron parameters in the general population.

The objectives of the study is to measure oral iron absorption and systemic iron utilization into red blood cells (RBC) using oral isotopic labels in subjects homozygotes for common variants of the TMPRSS6 gene with the SNP rs855791 (A736V); AA vs. VV subjects.

The aim is to conduct an iron absorption study in 80 Taiwanese women of reproductive age, non-pregnant, non-anemic, investigating the effect of the genetic variants of the SNP rs855791. The participants will be split in two groups of equal size; wild type AA vs. mutation VV. Iron absorption and systemic utilization will be assessed by two test meals containing stable isotopes of iron.The primary outcome of the trial is the oral iron absorption from a test meal as compared between the two genotypes AA vs. VV. Secondary outcomes are the comparison iron status markers between the two genotypes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Kaohsiung-Chang Gun Memorial Hospital

Kaohsiung City, Kaohsiung, 83301, Taiwan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects homozygotous for the for AA (CC), or VV (TT) variant of the SNP rs855791 of the TMPRSS6 gene.
  • Females 20 - 45 years of age (premenopausal status)
  • obtained informed consent
  • regular menstrual cycle, ± 2 days

Exclusion criteria

  • Pregnancy or lactating (assessed by pregnancy test and self-declaration, respectively)
  • Anemia defined as Hb < 120 g/L
  • Plasma ferritin < 30 µg/l, or > 120 µg/l
  • C-reactive Protein > 5 mg/l
  • Body weight > 65 kg
  • Body mass index (BMI) 18.5 - 25
  • Diagnosed metabolic or gastrointestinal disorders, eating disorders or food allergy to the ingredients of the test meal.
  • Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 6 months, prior the first study day.
  • Subjects who cannot be expected to comply with study protocol (e.g. non-residents).
  • Use of long-term medication during the study
  • Subjects that will take part of another clinical study at the same time or had within the last 30 days before the first study day
  • Intake of mineral/vitamin supplements 2 weeks before the first study day and during the study

Treatment and study plan

Testmeal A

Dietary Supplement

The tesmeal A is is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate

Testmeal B

Dietary Supplement

The tesmeal B is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate

Primary outcomes

  1. Change from baseline in the isotopic ratio of iron in blood at week 2

    Time frame: baseline, 2 weeks

    The change in the isotopic ratio of iron in blood will be measured after the administration of test meal including iron isotopes.

Secondary outcomes

  1. hepcidin

    Time frame: baseline

    fasting concentrations of plasma hepcidin in AA and VV variants of SNP rs855791

  2. iron status

    Time frame: baseline

    The difference in fasting concentrations of serum iron, transferrin saturation, serum ferritin, hemoglobin, erythrocyte volume in AA and VV variants of SNP rs855791

Sponsors and collaborators

Lead sponsor

Swiss Federal Institute of Technology

Other

Collaborators

  • Chang Gung Memorial Hospital

Registry information

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Oct 23, 2017
Registry last updated
Jun 12, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.